1 |
Abdulla, M. and Gruber, P. (2000) Role of diet modification in cancer prevention. Biofactors 12, 45-51.
DOI
|
2 |
Bosetti, C., Bertuccio, P., Negri, E., La Vecchia, C., Zeegers, M. P. and Boffetta, P. (2012) Pancreatic cancer: overview of descriptive epidemiology. Mol. Carcinog. 51, 3-13.
DOI
|
3 |
Butler, A. M., Scotti Buzhardt, M. L., Erdogan, E., Li, S., Inman, K. S., Fields, A. P. and Murray, N. R. (2015) A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion. Oncotarget 6, 15297-15310.
DOI
|
4 |
Calonghi, N., Pagnotta, E., Parolin, C., Mangano, C., Bolognesi, M. L., Melchiorre, C. and Masotti, L. (2007) A new EGFR inhibitor induces apoptosis in colon cancer cells. Biochem. Biophys. Res. Commun. 354, 409-413.
DOI
|
5 |
Chien, W., Lee, D. H., Zheng, Y., Wuensche, P., Alvarez, R., Wen, D. L., Aribi, A. M., Thean, S. M., Doan, N. B., Said, J. W. and Koeffler, H. P. (2014) Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFB, and mTOR signaling in vitro and in vivo. Mol. Carcinog. 53, 722-735.
DOI
|
6 |
Duan, J., Friedman, J., Nottingham, L., Chen, Z., Ara, G. and Van Waes, C. (2007) Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 6, 37-50.
|
7 |
El Fitori, J., Su, Y., Buchler, P., Ludwig, R., Giese, N. A., Buchler, M. W., Quentmeier, H., Hines, O. J., Herr, I. and Friess, H. (2007) PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer. Cancer 110, 1457-1468.
DOI
|
8 |
Hsu, C. C., Lien, J. C., Chang, C. W., Chang, C. H., Kuo, S. C. and Huang, T. F. (2013) Yuwen02f1 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation, NFB and MAPK activation. Biochem. Pharmacol. 85, 385-395.
DOI
|
9 |
Im, N. K., Jang, W. J., Jeong, C. H. and Jeong, G. S. (2014) Delphinidin suppresses PMA-induced MMP-9 expression by blocking the NF-kappaB activation through MAPK signaling pathways in MCF-7 human breast carcinoma cells. J. Med. Food 17, 855-861.
DOI
|
10 |
Lee, C. H., Jeon, Y. T., Kim, S. H. and Song, Y. S. (2007) NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29, 19-35.
DOI
|
11 |
Liu, Y., Cao, W., Zhang, B., Liu, Y. Q., Wang, Z. Y., Wu, Y. P., Yu, X. J., Zhang, X. D., Ming, P. H., Zhou, G. B. and Huang, L. (2013) The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy. Sci. Rep. 3, 3098.
|
12 |
Moon, J., Koh, S. S., Malilas, W., Cho, I. R., Kaewpiboon, C., Kaowinn, S., Lee, K., Jhun, B. H., Choi, Y. W. and Chung, Y. H. (2014) Acetylshikonin induces apoptosis of hepatitis B virus X proteinexpressing human hepatocellular carcinoma cells via endoplasmic reticulum stress. Eur. J. Pharmacol. 735, 132-140.
DOI
|
13 |
Raimondi, S., Maisonneuve, P. and Lowenfels, A. B. (2009) Epidemiology of pancreatic cancer: an overview. Nat. Rev. Gastroenterol. Hepatol. 6, 699-708.
DOI
|
14 |
Moser, C., Schachtschneider, P., Lang, S. A., Gaumann, A., Mori, A., Zimmermann, J., Schlitt, H. J., Geissler, E. K. and Stoeltzing, O. (2008) Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur. J. Cancer 44, 1577-1586.
DOI
|
15 |
Nishino, H., Tokuda, H., Murakoshi, M., Satomi, Y., Masuda, M., Onozuka, M., Yamaguchi, S., Takayasu, J., Tsuruta, J., Okuda, M., Khachik, F., Narisawa, T., Takasuka, N. and Yano, M. (2000) Cancer prevention by natural carotenoids. Biofactors 13, 89-94.
DOI
|
16 |
Pahl, H. L. (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18, 6853-6866.
DOI
|
17 |
Reddy, L., Odhav, B. and Bhoola, K. D. (2003) Natural products for cancer prevention: a global perspective. Pharmacol. Ther. 99, 1-13.
DOI
|
18 |
Tafani, M., Pucci, B., Russo, A., Schito, L., Pellegrini, L., Perrone, G. A., Villanova, L., Salvatori, L., Ravenna, L., Petrangeli, E. and Russo, M. A. (2013) Modulators of HIF1alpha and NFkB in cancer treatment: is it a rational approach for controlling malignant progression? Front. Pharmacol. 4, 13.
|
19 |
Wiench, B., Eichhorn, T., Paulsen, M. and Efferth, T. (2012) Shikonin directly targets mitochondria and causes mitochondrial dysfunction in cancer cells. Evid. Based Complement. Alternat. Med. 2012, 726025.
|
20 |
Zeng, Y., Liu, G. and Zhou, L. M. (2009) Inhibitory effect of acetylshikonin on human gastric carcinoma cell line SGC-7901 in vitro and in vivo. World J. Gastroenterol. 15, 1816-1820.
DOI
|